.jpg)
.jpg)
.jpg)
Lower respiratory tract infection (LRTI) is one of the most common acute reasons for patients to seek urgent medical assessment, accounting for 17 million consultations in the European Union and 11 million in the U.S. each year.1
Despite robust evidence highlighting little or no benefit from antibiotic treatment for most people presenting with respiratory tract infection (RTI) symptoms, these illnesses are still the commonest reason for antibiotic prescribing in primary care.2
Statistics indicate that 90% of RTIs are caused by viruses and, in these cases, antibiotics are unlikely to have any clinical benefit for the patient.3 In fact, 80% of LRTIs presenting in primary care are acute bronchitis. Despite evidence of little or no benefit from antibiotics, up to 80% of patients consulting for this condition are prescribed them.1
There is an obvious over-prescription of antibiotics for RTI in primary care. Antibiotic prescribing puts individuals at risk from side effects, encourages help-seeking behavior for mainly self-limiting illnesses, and puts both individuals and society at risk from increasing antibiotic resistance.2 Most RTIs are harmless, self-limiting and nearly all patients recover without any pharmaceutical intervention. Antibiotic treatment, in some cases, may be directly harmful due to adverse effects.3
Research indicates that countries’ antibiotic-prescribing rates are linked to resistance rates1,2 and, consequently, that the reduction of unnecessary prescribing, particularly for acute respiratory tract infections (ARTIs), could directly contribute to lower resistance.4 Interventions such as CRP point-of-care testing can help promote a more prudent use of antibiotics.5,6 Use of point-of-care tests for CRP have been shown to significantly reduce antibiotic prescribing for lower respiratory tract infections without compromising either patients’ recovery or satisfaction with care.7-12 It has also been shown that physicians with access to CRP tests significantly reduced antibiotic prescriptions in patients with rhinosinusitis.13
The Afinion™ CRP test is an important point-of-care assay to help discriminate serious illness such as pneumonia from often self-limiting illness like acute bronchitis and other RTI.14 Afinion™ CRP is a rapid in vitro diagnostic test for quantitative determination of C-reactive protein (CRP) in human blood; helping reduce diagnostic uncertainty and guiding antibiotic decision making during your patient’s visit. The fully automated Afinion™ CRP test provides, with excellent precision and user friendliness, an answer in 3-4 minutes.
C-reactive protein (CRP) is one of the cytokine induced acute-phase proteins, the levels of which rise during a response to infectious and non-infectious inflammatory processes.16,17 In healthy persons the serum or plasma CRP levels are below 5 mg/L.17,18 As elevated CRP levels are always associated with pathological changes, the CRP assay provides information for the diagnosis, therapy and monitoring of inflammatory diseases.15-18
*Product not available in US.
Learn more about Abbott tools for combating AMR at the Abbott myPOCacademy
https://campus.meplis.com/mypocacademy/us/en/tags/amr-and-antibiotic
Hear from the experts about the value of CRP POCT to combat AMR
© 2023 Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners. Any photos displayed are for illustrative purposes only. Any person depicted in such photos is a model. Products available in select markets only.
This website is governed by applicable U.S. laws and governmental regulations. The products and information contained herewith may not be accessible in all countries, and Abbott takes no responsibility for such information which may not comply with local country legal process, regulation, registration and usage.
Your use of this website and the information contained herein is subject to our Website Terms and Conditions and Privacy Policy. The companies, websites, products and services, and brands referenced and linked to from this website are not sponsored or endorsed by, or otherwise affiliated with, Abbott or TestTargetTreat.com. GDPR Statement. Interest-Based Ads.
The third-party trademarks, products and services referenced and linked to from this website are included for informational purposes only, and have not been tested or approved by Abbott or TestTargetTreat.com. Neither Abbott nor TestTargetTreat.com make any representations or warranties regarding third-party products or services, and shall not be liable for any claims arising from those products or services or your use thereof. See the Website Terms and Conditions for additional details.